Clinical trial
Dendritic Cell Vaccination During Lymphoid Reconstruction
NCT00313508 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00313508 |
|---|---|
| Title | Dendritic Cell Vaccination During Lymphoid Reconstruction |
| Official title | A Dose Ranging Trial of MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured Using Cytokines With Autologous Lymphocyte Infusion With or Without Escalating Doses of Fludarabine for Patients With Chemotherapy-naive Metastatic Melanoma |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI) |
| Enrollment | 18 |
| Start date | Feb 1, 2006 |
| Primary completion | Mar 1, 2012 |
| Completion | Mar 1, 2012 |
| First posted | Apr 12, 2006 |
| Last update posted | Feb 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: